
    
      This is a randomized, double-blind, placebo-controlled study to determine the safety and
      efficacy of SZC in ESRD subjects with hyperkalaemia and on stable haemodialysis. This study
      consists of a screening period, an 8-week randomized treatment period, and a follow-up
      period. Approximately 134 stable haemodialysis subjects with persistent pre-dialysis
      hyperkalaemia will be enrolled in the study across research sites in China.
    
  